Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)
Journal article
Howell I. et al, (2023), JMIR Research Protocols, 12, e46741 - e46741
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.
Journal article
Wing PAC. et al, (2023), PLoS pathogens, 19
Epithelial immune activation and intracellular invasion by non-typeable Haemophilus influenzae
Journal article
Brown MA. et al, (2023), Frontiers in Cellular and Infection Microbiology, 13
Editorial: MAIT cells come of age
Journal article
Corbett AJ. et al, (2023), Frontiers in Immunology, 14
MAIT cells and the microbiome.
Journal article
Jabeen MF. and Hinks TSC., (2023), Frontiers in immunology, 14
BIO-AST Biologics for chronic severe asthma: a network meta-analysis
Journal article
Crossingham I. et al, (2022), Cochrane Database of Systematic Reviews, 2022
Sub‐stratification of type‐2 high airway disease for therapeutic decision‐making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ ( FeNO ) framework
Journal article
Couillard S. et al, (2022), Respirology, 27, 573 - 577
Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing.
Journal article
Couillard S. et al, (2022), Thorax
Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies
Journal article
Jabeen MF. et al, (2022), Microbiology Spectrum, 10
The bacteriology of pleural infection (TORPIDS): an exploratory metagenomics analysis through next generation sequencing
Journal article
Kanellakis NI. et al, (2022), The Lancet Microbe, 3, e294 - e302
Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
Journal article
Couillard S. et al, (2022), ERJ Open Research, 00570 - 2021
Azithromycin for mild-to-moderate COVID-19 - Authors' reply.
Journal article
Hinks TSC. and ATOMIC2 trial authors None., (2021), The Lancet. Respiratory medicine, 9, e100 - e101
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells
Journal article
Zhuang X. et al, (2021), iScience, 24, 103144 - 103144
Subcutaneous omalizumab for people with asthma
Journal article
Donovan T. et al, (2021), Cochrane Database of Systematic Reviews, 2021
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.
Journal article
Hinks TSC. et al, (2021), The Lancet. Respiratory medicine
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells.
Journal article
Zhuang X. et al, (2021), bioRxiv
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
Journal article
Crossingham I. et al, (2021), Cochrane Database of Systematic Reviews
A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial
Journal article
Hinks TSC. et al, (2021)
A Randomised Clinical Trial of Azithromycin Versus Standard Care in Ambulatory COVID-19 – The ATOMIC2 Trial
Journal article
Hinks TSC. et al, (2021), SSRN Electronic Journal
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells
Journal article
Wing PAC. et al, (2021), Cell Reports, 35, 109020 - 109020